# IMpower150 (NCT02366143)

> A Study of Atezolizumab in Combination With Carboplatin Plus (+) Paclitaxel With or Without Bevacizumab Compared With Carboplatin+Paclitaxel+Bevacizumab in Participants With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02366143
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Hoffmann-La Roche
- Conditions: Carcinoma, Non-Small-Cell Lung
- Interventions: Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody; Bevacizumab; Carboplatin; Paclitaxel
- Enrollment: 1202
- Primary outcome: Progression Free Survival (PFS), as Determined by the Investigator in Arm B Versus Arm C in the Teff-high WT Population and ITT-WT Population
- Primary outcome: Overall Survival (OS) in Arm B Versus Arm C in ITT-WT Population
- Primary outcome: Overall Survival (OS) in Arm A Versus Arm C in ITT-WT Population

## Commentary we found

- Podcasts: 50
- YouTube: 37
- X threads: 27

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=impower150-nct02366143

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT02366143", "email": "<work email>"}; the inbox owner confirms by the emailed link.